利用RNA-seq探讨谷氨酰胺剥夺对喉癌细胞转录组的影响

doi:10.6040/j.issn.1673-3770.0.2021.090

摘要/Abstract

摘要： 目的利用RNA-seq技术研究谷氨酰胺剥夺对喉癌细胞基因表达谱的影响。方法 CCK8检测喉癌细胞增殖速度,RNA sequence检测转录组学的改变。结果谷氨酰胺剥夺限制喉癌细胞的增殖,转录组分析发现谷氨酰胺剥夺导致328个基因上调,210个基因下调;GO分析发现上述基因与细胞代谢、蛋白质和核苷酸的合成相关;KEGG信号通路分析发现上述基因与O-多聚糖、糖基磷脂酰肌醇的生物合成,果糖、甘露糖、氨基酸和核苷酸的代谢,P53信号通路相关;疾病富集发现差异表达的基因主要与头颈部肿瘤相关。结论谷氨酰胺剥夺限制核酸代谢、RNA和蛋白质的结合,影响P53信号通路。

关键词: 喉癌, 谷氨酰胺代谢, RNA测序

Abstract: Objective Glutamine is necessary for head and neck cancer cells to maintain maximum proliferation rate, this article used RNA sequence to explore the effect of glutamine deprivation on laryngeal cancer cell gene expression Changes. Methods The CCK8 assay measured laryngeal cancer cell proliferation rate, RNA sequence measured transcriptome changes of laryngeal cancer cells after glutamine deprivation, bioinformatics methods analyzed gene enrichment. Results Glutamine deprivation restricted laryngeal cancer cell proliferation, transcriptome analysis found that glutamine deprivation leads to 328 gene up-regulated and 210 genes down-regulated. GO analysis showed that the differentially expressed genes were mainly related to cell metabolism, organelle synthesis, protein and nucleotide synthesis. KEGG signaling pathway analysis showed that signaling pathways changes were mainly related to O-polysaccharides and glycosylphosphatidylinositol biosynthesis, fructose mannacil amino acids and nucleotides metabolism, and the P53 signaling pathway. Disease enrichment found that the differentially expressed genes were mainly related to head and neck carcinoma. Conclusion Glutamine deprivation restricts nucleic acid metabolism, RNA and protein binding, and affects the P53 signaling pathway.

Key words: Laryngeal cancer, Glutamine metabolism, RNA sequence

中图分类号:

R767.91

王晓亭,陈正侬,易红良. 利用RNA-seq探讨谷氨酰胺剥夺对喉癌细胞转录组的影响[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 26-31.

WANG Xiaoting, CHEN Zhengnong, YI Hongliang. Transcriptomic analysis of glutamine deprivation on laryngeal carcinoma cells[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(2): 26-31.

参考文献

[1] 徐进敬, 胡京华, 吴元庆, 等. CO₂激光显微手术在喉癌前病变和早期声门型喉癌中的应用[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 129-133. doi:10.6040/j.issn.1673-3770.0.2019.501. XU Jinjing, HU Jinghua, WU Yuanqing, et al. Applications of CO₂ lasermicrosurgery on laryngeal precancerous lesions and early glottic laryngeal carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 129-133. doi:10.6040/j.issn.1673-3770.0.2019.501.
[2] 谭凤武,邓亚萍,黎可华. 低温等离子射频消融与CO₂激光手术治疗早期声门型喉癌疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 63-71. doi:10.6040/j.issn.1673-3770.0.2019.570. TAN Fengwu, DENG Yaping, LI Kehua. The therapeutic effects of low temperature plasma radiofrequency ablation and CO₂ laser surgery on early glottic carcinoma: a Meta-analysis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(6): 63-71. doi:10.6040/j.issn.1673-3770.0.2019.570.
[3] 李晓明. 喉癌治疗中喉功能保留的历史、现状和未来[J]. 山东大学耳鼻喉眼学报, 2019, 33(4): 1-5. doi:10.6040/j.issn.1673-3770.1.2019.030. LI Xiaoming. History, current status and future of laryngeal function retention in laryngeal cancer treatment[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 1-5. doi:10.6040/j.issn.1673-3770.1.2019.030.
[4] Magrini SM, Buglione M, Corvò R, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial[J]. J Clin Oncol, 2016, 34(5): 427-435. doi:10.1200/JCO.2015.63.1671.
[5] Leone RD, Zhao L, Englert JM, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion[J]. Science, 2019, 366(6468): 1013-1021.doi:10.1126/science.aav2588.
[6] Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy[J]. Nat Rev Cancer, 2016, 16(11): 749. doi:10.1038/nrc.2016.114.
[7] Li T, Copeland C, Le A. Glutamine metabolism in cancer[J]. Adv Exp Med Biol, 2021, 1311: 17-38. doi:10.1007/978-3-030-65768-0_2.
[8] Bhutia YD, Babu E, Ramachandran S, et al. Amino acid transporters in cancer and their relevance to “glutamine addiction”: novel targets for the design of a new class of anticancer drugs[J]. Cancer Res, 2015, 75(9): 1782-1788. doi:10.1158/0008-5472.can-14-3745.
[9] van Geldermalsen M, Wang Q, Nagarajah R, et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer[J]. Oncogene, 2016, 35(24): 3201-3208. doi:10.1038/onc.2015.381.
[10] Sandulache VC, Ow TJ, Pickering CR, et al. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells[J]. Cancer, 2011, 117(13): 2926-2938. doi:10.1002/cncr.25868.
[11] Smith B, Schafer XL, Ambeskovic A, et al. Addiction to coupling of the Warburg effect with glutamine catabolism in cancer cells[J]. Cell Rep, 2016, 17(3): 821-836. doi:10.1016/j.celrep.2016.09.045.
[12] Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism[J]. Cell Metab, 2016, 23(1): 27-47. doi:10.1016/j.cmet.2015.12.006.
[13] Zhang J, Pavlova NN, Thompson CB. Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine[J]. EMBO J, 2017, 36(10): 1302-1315. doi:10.15252/embj.201696151.
[14] Yang LF, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism[J]. Annu Rev Biomed Eng, 2017, 19: 163-194. doi:10.1146/annurev-bioeng-071516-044546.
[15] Li L, Meng Y, Li ZY, et al. Discovery and development of small molecule modulators targeting glutamine metabolism[J]. Eur J Med Chem, 2019, 163: 215-242. doi:10.1016/j.ejmech.2018.11.066.
[16] Bott AJ, Shen JL, Tonelli C, et al. Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism[J]. Cell Rep, 2019, 29(5): 1287-1298.e6.doi:10.1016/j.celrep.2019.09.056.
[17] Cluntun AA, Lukey MJ, Cerione RA, et al. Glutamine metabolism in cancer: understanding the heterogeneity[J]. Trends Cancer, 2017, 3(3): 169-180. doi:10.1016/j.trecan.2017.01.005.
[18] Dejure FR, Eilers M. MYC and tumor metabolism: chicken and egg[J]. EMBO J, 2017, 36(23): 3409-3420. doi:10.15252/embj.201796438.
[19] Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction[J]. Proc Natl Acad Sci USA, 2008, 105(48): 18782-18787. doi:10.1073/pnas.0810199105.
[20] De Vitto H, Pérez-Valencia J, Radosevich JA. Glutamine at focus: versatile roles in cancer[J]. Tumour Biol, 2016, 37(2): 1541-1558. doi:10.1007/s13277-015-4671-9.
[21] Liu Y, He XC, Chen YL, et al. Long non-coding RNA LINC00504 regulates the Warburg effect in ovarian cancer through inhibition of miR-1244[J]. Mol Cell Biochem, 2020, 464(1/2): 39-50.doi:10.1007/s11010-019-03647-z.
[23] Yin L, Yan J, Wang YY, et al. TIGD1, a gene of unknown function, involves cell-cycle progression and correlates with poor prognosis in human cancer[J]. J Cell Biochem, 2019, 120(6): 9758-9767.doi:10.1002/jcb.28256.
[24] Liu QC, Guo L, Zhang S, et al. PRSS1 mutation: a possible pathomechanism of pancreatic carcinogenesis and pancreatic cancer[J]. Mol Med, 2019, 25(1): 44. doi:10.1186/s10020-019-0111-4.
[25] Lee SK, Park EJ, Lee HS, et al. Genome-wide screen of human bromodomain-containing proteins identifies Cecr2 as a novel DNA damage response protein[J]. Mol Cells, 2012, 34(1): 85-91.doi:10.1007/s10059-012-0112-4.
[26] Ge CQ, Li QF, Wang LP, et al. The role of axon guidance factor semaphorin 6B in the invasion and metastasis of gastric cancer[J]. J Int Med Res, 2013, 41(2): 284-292.doi:10.1177/0300060513476436.
[27] Cacace A, Sboarina M, Vazeille T, et al. Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism[J]. Oncogene, 2017, 36(15): 2074-2084.doi:10.1038/onc.2016.364.
[28] Sun NC, Liang Y, Chen YB, et al. Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis[J]. Int J Mol Med, 2019, 44(6): 2189-2200.doi:10.3892/ijmm.2019.4385.
[29] Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell[J]. Cell Death Differ, 2019, 26(2): 199-212. doi:10.1038/s41418-018-0246-9.
[30] Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response[J]. J Cell Sci, 2020, 133(5): jcs237453. doi:10.1242/jcs.237453.
[31] Akins NS, Nielson TC, Le HV. Inhibition of glycolysis and glutaminolysis: an emerging drug discovery approach to combat cancer[J]. Curr Top Med Chem, 2018, 18(6): 494-504. doi:10.2174/1568026618666180523111351.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed